http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001511149-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2848 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate | 1998-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001511149-A |
| titleOfInvention | Anti-αvβ3 recombinant humanized antibodies, nucleic acids encoding the same, and methods of use |
| abstract | (57) Abstract The present invention provides vitaxin antibodies and LM609-grafted antibodies that exhibit selective binding affinity for α v β 3 . A vitaxin antibody consists of at least one vitaxin heavy chain polypeptide and at least one vitaxin light chain polypeptide or a functional fragment thereof. Also provided are vitaxin heavy and light chain polypeptides, and functional fragments. The LM609-grafted antibody consists of at least one CDR-grafted heavy chain polypeptide and at least one CDR-grafted light chain polypeptide, or a functional fragment thereof. The present invention further provides a high affinity LM609 grafted antibody comprising one or more CDR having at least one amino acid substitution, wherein the alpha v beta 3 binding activity of high affinity LM609 grafted antibody , Is strengthened. Further provided are nucleic acids encoding vitaxin and LM609 grafted heavy and light chains, and nucleic acids encoding the parent non-human antibody LM609. Functional fragments of such encoding nucleic acids are also provided. The present invention also provides a method for inhibiting the function of α v β 3 . The method comprises the steps of contacting α v β 3 with a vitaxin or LM609 grafted antibody, or a functional fragment thereof, under conditions that permit binding to α v β 3 . Finally, the present invention provides a method of treating an α v β 3 -mediated disease. The method comprises the step of administering an effective amount of a vitaxin or LM609 grafted antibody, or a functional fragment thereof, under conditions that permit binding to α v β 3 . |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005510246-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010162025-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003525061-A |
| priorityDate | 1997-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 195.